Analysts spy dynamic market for new eosinophilic esophagitis therapies

Industry analyst GlobalData has provided research indicating that the market for eosinophilic esophagitis (EOE) treatments is rapidly changing in the USA.

While there are currently no US Food and Drug Administration-approved treatments for EOE, a broad range of pipeline drugs with diverse mechanisms of action promise to meet the high level of medical need in this setting.

According to new guidelines drawn up by The American Gastroenterological Association (AGA), the first-line approach for EOE management is dietary therapy, followed by corticosteroid treatments such as fluticasone and budesonide.